Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E </span>mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
In thyroid cancer, TPO expression is decreased partly by the BRAF(V600E) mutation, with direct impact on significant hormone production.
|
30742860 |
2019 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
<i>BRAF</i> V600E mutations have been successfully treated with targeted therapy in melanoma, non-small cell lung cancer, and thyroid cancer.
|
29295876 |
2018 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
In summary, the present study demonstrated that thyroid cancer harboring the BRAF V600E mutation was resistant to a selective BRAF inhibitor due to reactivation of the MAPK pathway.
|
29616135 |
2018 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
TERT promoter mutations were likely to occur in BRAF V600E positive TC.
|
30024548 |
2018 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BRAF V600E mutation was detected in the PTCs of the two patients with thyroid cancer.
|
29593792 |
2018 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
This represents a novel mechanism in BRAF V600E-promoted PTC aggressiveness and identifies WIPF1 as a novel therapeutic target for thyroid cancer.
|
27863429 |
2017 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation.
|
27880942 |
2017 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The BM probe not only enabled sensitive detection of two types of EGFR-associated point mutations located in GC-rich regions, but also successfully identified the BRAF V600E mutation in the serum from a thyroid cancer patient which could not be detected by the conventional sequencing method.
|
28201758 |
2017 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Triple combination of PLX4032, SAHA, and TSH is a specific robust regimen to restore RAI avidity in RAI-refractory BRAF V600E-positive thyroid cancer, which warrants clinical trials to confirm.
|
26751190 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given the strong genotype:phenotype correlation known to be present in thyroid cancer, the separation of BRAF(V600E)-like and RAS-like tumors has profound implications for its classification, especially the follicular variant of papillary carcinoma.
|
26569424 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
In this study, we investigated the relationship between the TME and thyroid cancer progression in a mouse model where thyroid-specific expression of oncogenic BRAF and loss of Pten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to poorly differentiated thyroid cancer (PDTC).
|
26818109 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.
|
26456083 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study also for the first time demonstrates an association of the BRAF(V600E) mutation with TC recurrence in pediatric patients.
|
26711586 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
We performed Sanger sequencing to detect BRAF V600E and TERT promoter mutations and both immunohistochemistry and fluorescence in situ hybridization to identify ALK rearrangement on 243 thyroid cancers.
|
26857243 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The presence of BRAF V600E mutation in FNAC material is always associated with the presence of TC.
|
26884114 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Genetic alterations occurring in thyroid cancer frequently affect the RAS/RAF/MEK/ERK-pathway such as the oncogenic, kinase-activating BRAF(V600E) mutation.
|
26892809 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thus, TERT with promoter mutations represents a prominent new oncogene in thyroid cancer and the mutations are promising new diagnostic and prognostic genetic markers for thyroid cancer, which, in combination with BRAF V600E mutation or other genetic markers (e.g.
|
26733501 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
The CVF approach identified single-mutation driver candidates, such as BRAF V600E in the thyroid cancer dataset.
|
26543077 |
2016 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Evidence has also shown that the detection of the BRAF(V600E) mutation in cancer is crucial in order to identify novel avenues for thyroid cancer treatment.Based on the BRAF kinase structure, novel drugs can potentially be designed to target oncogenic BRAF in cancer therapeutics.
|
25961545 |
2015 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Here, we show that depletion of RAF-1, a RAF family member with a poorly defined role in TC, decreases proliferation and increases apoptosis in TPC-1 cells and, less significantly, in cells harboring a BRAF(V600E) or HRAS(G13R) mutations, but without affecting ERK activation.
|
26265449 |
2015 |
Malignant neoplasm of thyroid
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overexpression of HO-1 in a subset of thyroid cancers is associated with tumour aggressiveness and BRAF V600E expression.
|
25262966 |
2015 |